Quantcast

Industry news that matters to you.  Learn more

Chronix Biomedical Adds State-of-the-art Mass Seqeuncing Capabilities to Accelerate Development of it’s DNA Biomakers for Early Detection of Cancer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany’s first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix’s long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.